These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17431594)

  • 1. Recent progress in analytical instrumentation for glycemic control in diabetic and critically ill patients.
    Kondepati VR; Heise HM
    Anal Bioanal Chem; 2007 Jun; 388(3):545-63. PubMed ID: 17431594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose control in the intensive care unit.
    Fahy BG; Sheehy AM; Coursin DB
    Crit Care Med; 2009 May; 37(5):1769-76. PubMed ID: 19325461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control in the critically ill: What have we learned since NICE-SUGAR?
    Krinsley JS
    Hosp Pract (1995); 2015; 43(3):191-7. PubMed ID: 26224425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia.
    Choe C; Edelman SV
    South Med J; 2007 Nov; 100(11):1123-31. PubMed ID: 17984745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glycaemia control in critically ill patients is justified and effective].
    Rybka J
    Vnitr Lek; 2010 Sep; 56(9 Suppl):977-87. PubMed ID: 21137171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How I explore...glycemic kinetics by continuous glucose monitoring].
    Radermecker RP; Magis D; Sélam JL; Scheen AJ
    Rev Med Liege; 2003 Mar; 58(3):164-7. PubMed ID: 12723510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk.
    Gerich JE; Odawara M; Terauchi Y
    Curr Med Res Opin; 2007 Aug; 23(8):1791-8. PubMed ID: 17610805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in practical endocrinology. The Glucosensor Unitec Ulm--a portable monitor for continuous blood glucose measurement.
    Brückel J; Zier H; Kerner W; Pfeiffer EF
    Horm Metab Res; 1990 Jul; 22(7):382-4. PubMed ID: 2401447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of premorbid diabetic status on the relationship between the three domains of glycemic control and mortality in critically ill patients.
    Krinsley JS; Meyfroidt G; van den Berghe G; Egi M; Bellomo R
    Curr Opin Clin Nutr Metab Care; 2012 Mar; 15(2):151-60. PubMed ID: 22234163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance assessment of a glucose control protocol in septic patients with an automated intermittent plasma glucose monitoring device.
    Umbrello M; Salice V; Spanu P; Formenti P; Barassi A; Melzi d'Eril GV; Iapichino G
    Clin Nutr; 2014 Oct; 33(5):867-71. PubMed ID: 24169498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous glucose monitoring (CGM)].
    Tsujino D; Utsunomiya K
    Rinsho Byori; 2014 Jan; 62(1):53-9. PubMed ID: 24724427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding glycemic control in the critically ill: 2011 update.
    Krinsley JS
    Hosp Pract (1995); 2011 Apr; 39(2):47-55. PubMed ID: 21576897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycemic management: six and one-half years experience at a university-affiliated community hospital.
    Krinsley JS
    Semin Thorac Cardiovasc Surg; 2006; 18(4):317-25. PubMed ID: 17395028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The optimal blood glucose target in critically ill patient: comparison of two intensive insulin therapy protocols].
    Raurell Torredà M; del Llano Serrano C; Almirall Solsona D; Catalan Ibars RM; Nicolás Arfelis JM
    Med Clin (Barc); 2014 Mar; 142(5):192-9. PubMed ID: 23490488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.
    Pinelli NR; Jones MC; Monday LM; Smith Z; Rhoney DH
    Ann Pharmacother; 2012 Jan; 46(1):124-9. PubMed ID: 22202493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose control in critically ill patients.
    Flower O; Finfer S
    Intern Med J; 2012 Jan; 42(1):4-6. PubMed ID: 22276558
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards smart tattoos: implantable biosensors for continuous glucose monitoring.
    Heo YJ; Takeuchi S
    Adv Healthc Mater; 2013 Jan; 2(1):43-56. PubMed ID: 23184404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice of strict glycemic control in critically ill patients.
    Schultz MJ; de Graaff MJ; Royakkers AA; van Braam Houckgeest F; van der Sluijs JP; Kieft H; Spronk PE
    Med Sci Monit; 2008 Nov; 14(11):RA191-7. PubMed ID: 18971884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus recommendations for the management of hyperglycaemia in critically ill patients in the Indian setting.
    Mukherjee JJ; Chatterjee PS; Saikia M; Muruganathan A; Das AK;
    J Assoc Physicians India; 2014 Jul; 62(7 Suppl):16-25. PubMed ID: 25668933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.